Peyronie Disease Clinical Trial
Official title:
Non-ablative Radiofrequency and Low-intensity Shock Wave Therapy in Fibrotic Plaque in Men With Peyronie's Disease: Case Series
The goal of this one arm clinical trial is to evaluate the safety and describe the clinical response of non-ablative radiofrequency treatment associated with shockwave therapy in men with Peyronie's disease. The main question[s] it aims to answer are: • is the treatment safe? • is there any clinical response to the proposed treatment? Participants will respond to five validated questionnaires: International Index of Erectile Dysfunction (IIEF-5), Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36), Peyronie's Disease Questionnaire (PDQ), Scale Hospital for Anxiety and Depression (SHAD) and the Erection Quality Questionnaire (EQQ); will undergo a physical assessment that includes palpation of the fibrotic plaque on the penis, pharmacological induction of erection, and assessment of the size of the fibrotic plaque through ultrasound. Every five sessions, the participant's degree of satisfaction will be measured using a 5-point Likert scale, as well as the evolution of symptoms will also be observed, using a 10-point Visual Analogue Scale (VAS) and penile pain, if present. The entire evaluation protocol will be applied before (pre-test), after treatment (post-test) and 1 month after the end of treatment. Volunteers will be monitored by telephone to verify the long-term response after 3, 6, 9 and 12 months of completed treatment in relation to the Likert scale and VAS. The treatments they'll be given are • of monopolar non-ablative radiofrequency associated with • low-intensity shock wave therapy.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | June 2026 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Clinical complaint related to Peyronie's disease; - At any stage of the disease (acute or chronic). Exclusion Criteria: - Users of a pacemaker, cardiac defibrillator implant or any other electromagnetic implant; - Metallic implants over or under the area to be treated. |
Country | Name | City | State |
---|---|---|---|
Brazil | Centro de Atenção ao Assoalho Pelvico | Salvador | Ba |
Lead Sponsor | Collaborator |
---|---|
Centro de Atenção ao Assoalho Pélvico |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to sexual function. | It will be measured by the questionnaire International Index of Erectile Dysfunction (IIEF-5). Lower values represent worse sexual function and are categorized as follows: 5-7 points represents severe erectile dysfunction, 8-11 points represents moderate erectile dysfunction, 12-16 represents mild to moderate erectile dysfunction, 17 -21 represents mild erectile dysfunction and 22-25 means no erectile dysfunction. | From enrollment to the end of treatment till 8 weeks, then at 1, 3, 6, 9 and 12 months. | |
Primary | It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to pain. | The level of pain will be assess by the question three questions of Peyronie's Disease Questionnaire (PDQ). Each of the three questions score from 0 to 10, so the total range will be from 0 to 30. The lower the score, the less pain the patient feels. | From enrollment to the end of treatment till 8 weeks, then at 1, 3, 6, 9 and 12 months. | |
Primary | It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a safe technique that leads to a satisfactory clinical response in relation to penile erection. | The quality of penile erection will be measured by the Quality of Erection Questionnaire. The final score can vary between 0 and 100 points, with the higher the score, the better the quality of the erection. | From enrollment to the end of treatment till 8 weeks, then at 1, 3, 6, 9 and 12 months. | |
Secondary | It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a technique that promotes a positive impact on quality of life and psycho-emotional aspects of anxiety and depression. | It will be measured by the questionnaire Medical Outcomes Study 36 - Item Short - Form Health Survey (SF-36). The final score for each domain ranges from 0 to 100 (there are two - body and mental), there is no cutoff point and higher scores indicate a better health status. | From enrollment to the end of treatment till 8 weeks, then at 1, 3, 6, 9 and 12 months. | |
Secondary | It is estimated that non-ablative RF associated with low-intensity SWT in patients with Peyronie Disease is a technique that promotes a positive impact on psycho-emotional aspects of anxiety and depression. | It will be measured by the questionnaire Scale Hospital for Anxiety and Depression. It is composed of two subscales, one for anxiety and the other for depression, with seven items each. The global score on each subscale ranges from 0 to 21. The lower the score, the lower level of anxiety/or depression. | From enrollment to the end of treatment till 8 weeks, then at 1, 3, 6, 9 and 12 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03774264 -
Treatment Response to Xiaflex for Men With Peyronie's Disease
|
||
Recruiting |
NCT05777031 -
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
|
Phase 4 | |
Active, not recruiting |
NCT05871177 -
Safety and Efficacy of Intralesional HiLow Hyaluronic Acid in the Treatment of Peyronie's Disease (PD)
|
N/A | |
Recruiting |
NCT05768867 -
French Translation and Validation of the PEYronie's Disease QUESTionnaire
|
||
Recruiting |
NCT04512287 -
PRP for Treatment of Peyronie's Disease
|
Phase 2 | |
Withdrawn |
NCT05646602 -
Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
|
N/A | |
Recruiting |
NCT03530540 -
Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.
|
N/A | |
Completed |
NCT04052217 -
Does Size Matter: A Single Case Experimental Design of Limiting the Depth of Penetration During Intercourse
|
N/A | |
Recruiting |
NCT06065436 -
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
|
N/A | |
Recruiting |
NCT05316714 -
Novel Nanofat Regenerative Surgical Technique for Peyronies' Disease Treatment
|
N/A | |
Completed |
NCT04370652 -
Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum
|
||
Active, not recruiting |
NCT05480683 -
Pelvic CT With Agatston Calcium Score for Peyronie Disease
|
N/A | |
Recruiting |
NCT04821115 -
Safety and Efficacy of Low-intensity Shockwave Therapy for Peyronie's Disease
|
N/A |